Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JANX013 and JANX007 in mCRPC
NCT07813637Phase 1Recruiting
- Sponsor
- Janux Therapeutics
- Start
- Sep 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of JANX013 and JANX007 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Janux Therapeutics. Primary endpoints: Incidence of adverse events, serious adverse events, and dose-limiting toxicities at 2 years and Incidence of cytokine release syndrome at 2 years. Started Sep 2026; status: recruiting.
02
Drugs
JANX013JANX007
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07813637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07813637.